YC F25
Exonic
Unsupervised Biological AI
About
What if you could train a biological foundation model on... the entire internet? Exonic is pioneering a new generation of biological foundation models, focused on heterogeneous, unstructured, and noisy datasets. Our first application is the design of safer gene therapies. In 2025, we used AI to set a new state of the art in liver cancer targeted gene therapy, validated in vitro in our lab in San Francisco. So far in 2026, we have trained a new model with unprecedented zero-shot generalization on genomic regulatory expression in hold-out biosample datasets. More to be shared soon.
Founder
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Exonic.
See family office activityIndustry & Focus
HealthcareDrug Discovery and Delivery